+86-28-82633987
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
88.3800
2.4230
2.4215
.2042
3.5924
3.3245
High
86.4527
3.2674
No
No
No
No
No
No
0.0
Yes
No
No
No
Dehydrodehydrodehydro-dehydro-guaiac alcohol (CAS No.: 28199-69-1), as a natural product, belongs to the category of guaiacin compounds and has attracted widespread attention in the field of natural product pharmacology in recent years due to its unique chemical structure and diverse bioactivity. This compound is not only an important component of guaiacin-based lignin, but also a key intermediate for various secondary metabolites in plants. With further research into its molecular mechanisms, dihydrodehydrodiguaiacillo-based alcohol has shown significant potential in anti-inflammatory, antioxidant, and neuroprotective effects, especially exhibiting unique activity in regulating inflammation-related signaling pathways, making it one of the hotspots in the development of natural anti-inflammatory drugs.
This paper will systematically review the chemical structure and physicochemical properties, plant origin and extraction methods, pharmacological activity and mechanism of action of dihydrodehydrodehydroguacinol (MDVC), druggability evaluation and pharmacokinetic characteristics, and, combined with the latest research progress, explore its clinical application prospects and future research directions, aiming to provide a theoretical foundation and scientific basis for drug development of this natural product.
The chemical name of dihydrodehydroguaiaso-based alcohol is (2S,3R)-dihydrodehydrogiasol, and it is an important member of guaiacinophenol compounds. Its molecular formula is C20H24O6, and its molecular weight is 360.4060. This compound contains a benzofuran ring with a primary alcohol functional group and serves as the enantiomer of (2R,3S)-dihydrodehydrobispur alcohol. The stereochemical characteristics of its molecular structure have a significant impact on its biological activity.
In terms of physicochemical properties, the LogP value of dihydrodehydrodeshydroguaiacithol alcohol is 2.4230, showing moderate lipid solubility that facilitates its penetration through cell membranes. The polar surface area (TPSA) is 88.38 Ų, suggesting that it contains certain polar groups that may affect its water solubility and bioavailability. With a water solubility of 0.2042, it is a low-solubility compound, but its high blood-brain barrier permeability suggests potential central nervous system activity. Additionally, the hERG channel inhibition test results were negative, indicating a low risk of cardiotoxicity; The Ames test result was 0.0, indicating no significant mutagenicity and relatively high safety.
Dihydrodehydroguaiasine alcohol is mainly found in various woody plants, especially in the lignin structural units of pine family plants and certain broadleaf woods. As an important component of guaiacesis-based lignin, this compound plays a key role in secondary plant metabolism, participating in lignin biosynthesis and structural stability.
Traditionally, dihydrodehydroguaiastinol can be obtained by isolating the hydrolysate product of lignin monomers extracted from plant xylem. Common extraction methods include organic solvent extraction, acid-base hydrolysis, and supercritical fluid extraction. The typical steps are: first, plant powder is extracted using polar organic solvents such as ethanol or methanol, then hydrolyzed under acidic or alkaline conditions to release the bound dihydrodehydrodiguaiacinso-based alcohol. After liquid-liquid separation and column chromatography purification (such as silica gel columns and reversed-phase high-performance liquid chromatography), high-purity target compounds are obtained.
In recent years, with the development of green chemistry, ultrasound-assisted extraction and microwave-assisted extraction technologies have also been applied to the efficient extraction of dihydrodehydrodehydrodiguaiacinol, significantly improving extraction efficiency and purity, reducing the use of organic solvents, and meeting the needs of sustainable development.
Pharmacological activity studies of dihydrodehydrodehydro-diguaiacinsolene alcohol mainly focus on its anti-inflammatory effects and its application in related disease models. Numerous in vitro and in vivo experiments have shown that this compound can significantly inhibit the production of inflammatory mediators, reduce inflammatory responses, and have potential value in treating inflammatory diseases.
As one of the most prominent natural products with anti-inflammatory activity, dihydrodehydrodiguaiasin glycol regulates inflammatory signaling pathways through multiple targets and inhibits the expression of pro-inflammatory cytokines. Research shows that this compound can effectively downregulate the release of key inflammatory factors such as IL-6 and TNF-α, reducing infiltration of inflammatory cells and tissue damage. Additionally, it inhibits the activity of cyclooxygenases (PTGS1 and PTGS2) and induced nitric oxide synthase (NOS2), reducing the production of inflammatory mediators such as prostaglandins and nitric oxide.
Dihydrodehydrodiguaiasin glycol has excellent blood-brain barrier penetration, enabling it to demonstrate potential neuroprotective effects in central nervous system diseases. The study found that this compound demonstrated analgesic effects by regulating the TRPV1 and TRPA1 ion channels, reducing neuroinflammation and pain perception. Additionally, its regulation of the apoptosis-related protein CASP1 helps inhibit inflammatory apoptosis of nerve cells and protects nerve function.
Oxidative stress is an important pathological mechanism in various inflammations and chronic diseases. Dihydrodehydro-diguaiasosolol activates the NFKB1 signaling pathway, regulates the cell's antioxidant defense system, lowers reactive oxygen species (ROS) levels, alleviates oxidative damage, and further exerts its anti-inflammatory and cell-protective effects.
The bioactivity of dihydrodehydrodiguaiasoligiaminel-based alcohol depends on its regulation of various inflammation-related molecular targets, forming a complex signaling network.
IL-6 and TNF-α are key cytokines in inflammatory responses, involved in immune regulation and the inflammatory cascade. Dihydrodehydroguaiasinolein can inhibit the gene expression and secretion of these cytokines, reducing inflammatory responses. Its mechanism may involve inhibiting the activation of STAT3 transcription factors, blocking IL-6-mediated signaling, and reducing the transcription of pro-inflammatory genes.
STAT3, as an intracellular signal transduction and transcription activator, plays an important role in inflammation and tumor development. Dihydrodehydrodeshydroguaiafendiene glycol exerts anti-inflammatory and antitumor potential by inhibiting STAT3 phosphorylation and nuclear translocation, blocking its regulation of downstream inflammatory genes.
CASP1 is a key enzyme for activating inflammasomes, mediating the maturation and release of the pro-inflammatory cytokine IL-1β. Dihydrodehydrodiguaiacinsol glycol inhibits CASP1 activity, reduces activation of inflammasomes, lowers inflammatory cascade reactions and apoptosis, and protects tissues from inflammatory damage.
TRPV1 and TRPA1 are non-selective cation channels in sensory nerves involved in the transmission of pain and inflammation signals. Dihydrodehydroguaiacillobol has analgesic and neuroprotective effects by modulating the activity of these channels, reducing neuroinflammation and pain responses.
PTGS1 and PTGS2 (i.e., COX-1 and COX-2) are key enzymes in prostaglandin synthesis and participate in the production of inflammatory mediators. NOS2 catalyzes the induction of nitric oxide and is an important regulator of inflammatory responses. Dihydrodehydrodiguaiacinsol glycol exerts anti-inflammatory effects by inhibiting the expression and activity of these enzymes, reducing the formation of inflammatory mediators.
NFKB1 is a core transcription factor in inflammatory responses, regulating the expression of various pro-inflammatory genes. Dihydrodehydroguaiasin glycol can inhibit NFKB1 activation, prevent its nuclear translocation, reduce transcription levels of inflammatory genes, and alleviate inflammatory responses.
Druggability is a key consideration in the development of natural product drugs. Dihydrodehydrodiguaisosin wood-based alcohol exhibits good properties in terms of pharmacokinetics and safety.
Its moderate lipophilic solubility (LogP=2.4230) and low polar surface area (TPSA=88.38) facilitate its oral absorption and cell membrane penetration. High blood-brain barrier permeability indicates that this compound has good distribution potential in the central nervous system, making it suitable for developing drugs related to neurological diseases.
Currently, research on the metabolic pathways of dihydrodehydrodiaguaiasinol is relatively limited, but the phenolic hydroxyl and alcohol groups present in its structure may serve as metabolic sites for hepatic enzyme systems (such as cytochrome P450). It is expected to metabolize through corresponding oxidation and binding reactions, with excretion mainly via the kidneys and biliary tract.
The hERG channel inhibition test results were negative, indicating a low risk of cardiotoxicity and a reduced risk of side effects such as arrhythmias. The Ames test result was 0.0, indicating no mutagenicity, high safety, and suitability for further drug development.
Due to its structural characteristics, dihydrodehydrodiaguaiasin glycol may interact with various drug-metabolizing enzymes and transporters. Future evaluations are needed to systematically evaluate its effects on the cytochrome P450 enzyme system and drug transporters to avoid potential drug interactions.
Dihydrodehydrodiguaiacine ligenol demonstrates broad clinical application potential due to its remarkable anti-inflammatory and neuroprotective activities. Its application prospects in chronic inflammatory diseases (such as rheumatoid arthritis and inflammatory bowel disease), neurodegenerative diseases (such as Alzheimer's disease and Parkinson's disease), and pain management are promising.
Future research should focus on:
Preclinical efficacy and safety evaluation: Systematic in vivo pharmacodynamic and toxicological studies to clarify effective dose ranges and safety windows.
Pharmacokinetic optimization: Improving bioavailability and in vivo stability through structural modification or drug carrier technologies.
In-depth analysis of the mechanism of action: Using multi-omics techniques to reveal its specific regulatory mechanisms in cellular signaling networks, expanding its indication range.
Combination therapy strategies: Explore synergies with existing anti-inflammatory or neuroprotective drugs to enhance treatment outcomes.
Clinical trial design: Conduct early-stage clinical trials to verify safety and efficacy, laying the foundation for subsequent drug development.
As a naturally occurring product with a unique structure and rich biological activity, dihydrodehydrodigiagrosin wood-based alcohol shows broad research and application prospects in the fields of anti-inflammation and neuroprotection. Its multi-target mechanism of action and excellent druggability provide valuable resources for the development of novel natural drugs. In the future, through multidisciplinary collaboration and combining modern medicinal chemistry, molecular biology, and clinical medical research methods, dihydrodehydrodivinyl ligenol is expected to become an important candidate drug for treating inflammation and related diseases, promoting the development and innovation of natural product pharmacology.
Shenshuai
Wenjing
Hedandan
